

TEL : 0091- 217 - 2310824
: 0091- 217 - 2451500
FAX : 0091- 217 - 2451521
E-MAIL : info@balajiamines.com
WEBSITE : http://www.balajiamines.com

Balaji



ISO 45001:2018
ISO 14001:2015
ISO 9001:2015



www.tuv.com
ID 9105038797

CIN : L24132MH1988PLC049387

AMINES LIMITED

... A Speciality Chemical Company

Regd. Off. : 'Balaji Towers' No. 9/1A/1,
Hotgi Road, Aasara Chowk, Solapur - 413 224,
Maharashtra. (India)

29th July, 2026

To,
The General Manager-Department of
Corporate Services,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001.

The Manager-Listing Department,
National Stock Exchange of India Limited,
"Exchange Plaza", 5th Floor,
Plot No.C/1, G Block, Bandra-Kurla Complex,
Bandra (East), Mumbai – 400 051.

Scrip Code : 530999

Symbol : BALAMINES

Dear Sir/Madam,

Sub.: Investor Presentation on Q1 FY27 Financial Results

Ref.: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to the Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Investor Presentation on Q1 FY27 Financial Results.

This Investor Presentation may also be accessed on the website of the Company at <https://www.balajiamines.com/investor-relations.php>.

This is for your kind information and records.

Thanking you,

Yours faithfully,

For Balaji Amines Limited

Abhijeet Kothadiya
Company Secretary & Compliance Officer

Encl.: a/a

INDIA FIRST.

Building What **India** Needs Before **India**
Asks for It.

BALAJI AMINES LIMITED
Investor Presentation | Q1FY27

This presentation and the accompanying slides (the “Presentation”), which have been prepared by **Balaji Amines Limited** (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections. All Maps used in the presentation are not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness.



FINANCIAL HIGHLIGHTS Q1FY27



Key Highlights of the Quarter



Mr. Dundurapu Ram Reddy
Managing Director

We have commenced FY27 on a strong note, delivering healthy operational and financial performance with resilient margins, supported by improving demand across key end-user industries. Our diversified portfolio, integrated manufacturing platform and strong customer relationships have enabled us to capitalise on operational efficiencies and sustain performance despite global macroeconomic headwinds and the West Asia crisis.

During the quarter, we achieved a significant milestone with the commissioning of India's first commercial-scale 100,000 TPA Dimethyl Ether plant - an important step in our vision to diversify into new-age chemicals and alternate fuels, while reinforcing our commitment to import substitution.


Our NMM and Acetonitrile expansion projects remain firmly on track for commissioning by the end of the financial year, and the expansion at Balaji Speciality Chemicals Limited is progressing as planned. Backed by a healthy order pipeline, improving demand and disciplined execution, we remain confident of delivering sustainable growth in the coming years.




Financial highlights – Q1 FY27

STANDALONE


Total Revenue (INR Cr)




EBITDA (INR Cr)



PAT (INR Cr)




EBITDA & PAT MARGIN (%)




CONSOLIDATED


Total Revenue (INR Cr)




EBITDA (INR Cr)



PAT (INR Cr)



EBITDA & PAT MARGIN (%)



Consolidated Statement of Profit & Loss

Particulars (Rs.Crs.)	Q1FY27	Q1FY26	Y-o-Y	Q4FY26	Q-o-Q	FY26
Revenue from Operations	456	358		395		1425
Other Income	6	9		8		29
Total Revenue	461	367	25.73%	403	14.64%	1454
Total Raw Material	253	212		221		796
Employee Expenses	26	20		26		84
Other Expenses	61	71		53		279
EBITDA	121	63	91.51%	102	19.03%	294
EBITDA Margin (%)	26%	17%		25%		20%
Depreciation	14	14		14		56
EBIT	108	49	117.77%	88	22.24%	238
EBIT Margin (%)	23%	16%		22.3%		13.8%
Finance Cost	1	1		2		5
Profit before Tax	106	49	118.14%	86	23.69%	232
Profit before Tax(%)	23%	13%		21%		16%
Tax	28	12		21		63
Profit After Tax	78	37	110.19%	65	20.75%	169
PAT Margin (%)	17%	10%		16%		12%
EPS (As per Profit after Tax)	23.13	11.73		19.99		51.6




COMPANY OVERVIEW



WE BUILT INDIA'S 1st INDIGENOUS TECHNOLOGY FOR MANUFACTURING ALIPHATIC AMINES


Driven by innovation and import substitution, Balaji Amines continues to strengthen its specialty chemicals portfolio through differentiated products and disciplined expansion.





4 Manufacturing Locations

Strong multi-location manufacturing base



2 Speciality Chemical Units (BSCL)

Focus on High- Value Speciality Chemicals



Operations across Maharashtra & Telangana

Strategically located for scale and efficiency



Balaji Amines Ltd

BALAJI AMINES

(Core Manufacturing)

Leading manufacturer of aliphatic amines and speciality chemicals

Unit I
Solapur

Unit II
Telangana

Unit III
Solapur

Unit IV
Solapur

BALAJI SPECIALITY CHEMICALS LTD (Subsidiary)

Expanding the portfolio of speciality for high-growth industries

BSCL Unit I
Solapur

BSCL Unit II
Solapur



Hotel Balaji Sarovar

Hospitality Division

Manufacturing Locations – Built for Scale

BALAJI AMINES

Unit I – Solapur

Key Products:

- Methylamines
- Ethyl amines
- Morpholine
- Isopropyl amines (MIPA)
- Dimethylamine (DMA)
- Dimethyl Acetamide
- Dimethyl Urea
- Choline Chloride and other derivatives
- Dimethyl Amino Ethanol (DMAE)
- Diethyl Amino Ethanol (DEAE)

Unit II – Telangana

Key Products:

- Dimethylamine (DMA), Hydrochloride (HCl)

Unit III – Solapur

Key Products:

- Dimethyl Formamide
- Morpholine
- Acetonitrile
- Polyvinylpyrrolidone
- Methylamines
- Dimethyl Amine Hydrochloride
- Gamma-Butyrolactone
- N-Methyl Pyrrolidone
- 2-Pyrrolidone

Unit IV – Solapur

Key Products:

- Ethyl amines
- Methylamines
- N-Butylamine
- Dimethyl Carbonate (DMC)
- Propylene Carbonate (PC)
- Propylene Glycol (PG)
- Dimethyl Ether (DME)
- N-Methyl Morpholine (NMM)

Certifications:

- **ISO 9001:2015**
Quality Management Systems
- **ISO 14001:2015**
Environmental Management
- **ISO 45001:2018**
Occupational Health & Safety
- **WHO-GMP**
Required for pharma-linked regulated markets
- **Three- Star Export House**
- **REACH**
- **FAMI-QS**

BALAJI SPECIALITY CHEMICALS LTD (BSCL)

BSCL Unit I

Key Products Include:

- EDA
- DETA
- TETA
- Piperazine
- AEEA
- AEP

BSCL Unit II

Key Products Include:

- HCN
- Sodium Cyanide
- EDTA
- EDTA – 2Na
- Cyanation R&D plant

Certifications:

- **ISO 9001:2015**
- **ISO 14001:2015**
- **ISO 45001:2018**
- **REACH –EDA & DETA**
- **Two-Star Export House**

Commissioning key projects while advancing the next phase of speciality chemicals expansion.



DME Successfully Commissioned (Q1 FY27)

STATUS: OPERATIONAL

- 100,000 TPA DME plant commissioned in Q1 FY27, marking India's first commercial-scale DME manufacturing facility.
- Creates exposure to clean fuel, LPG blending and aerosol propellant applications, strengthening the Company's energy transition portfolio.



NMM & ACN Expansion Progressing as Planned

STATUS: UNDER EXECUTION

- N-Methyl Morpholine (NMM) project progressing expected towards commissioning during FY27.
- Acetonitrile (ACN) expansion under execution, expected to be commissioned during FY27, supporting a broader speciality chemicals portfolio.



R&D Mechanism

IN-HOUSE R&D PROGRAMME

- Higher utilization of recently commissioned capacities expected to improve operational efficiency.
- Ongoing capacity additions continue to strengthen the Company's speciality chemicals platform.

As new capacities come on stream and ongoing projects progress toward commissioning, Balaji Amines is well positioned to leverage emerging opportunities in speciality chemicals, supporting long-term growth and value creation.

Driving import substitution through phased commissioning of high-value speciality chemical platforms

BSCL Unit II – Phase I Progress

STATUS: UNDER EXECUTION



- Greenfield project comprising HCN, Sodium Cyanide, EDTA & EDTA-2Na under execution.
- Commissioning targeted by end-FY27, creating a new speciality chemicals platform for pharmaceuticals, agrochemicals, mining and water treatment.

BSCL Unit I – EDA Derivatives Platform

STATUS: UNDER EXECUTION



- EDA derivatives project (DETA, TETA, PIP, AEEA & AEP) progressing as planned.
- Commissioning targeted during FY27, expanding the company's portfolio of high-value speciality amines.

Phase II Expansion

STATUS: PLANNED



- Tri Ethyl Ortho Formate (TEOF) identified as the next phase of expansion.
- Expands BSCL's value-added product portfolio and supports future commercialization.

CYANATION R&D PROCESS

IN-HOUSE R&D PROGRAMME



- Translating complex cyanide chemistry processes into commercial production to replace current import dependencies for domestic pharma and agrochemical sectors

BSCL is progressing through a phased expansion program that strengthens Company's speciality chemicals platform, enhances import substitution capabilities, and creates long-term growth opportunities across regulated and industrial markets.

Capex-to-Cashflow Inflection

- **₹1000 Cr+** expansion cycle nearing completion on consolidated basis
- FY27 volume growth guided at **10-15%**, medium-term growth at **20-30%**
- Earnings acceleration expected as **DME, NMM, ACN** and BSCL projects ramp up

Unique Import-Substitution Franchise

- Only Indian producer of **Electronic Grade DMC** for EV battery applications
- India's first commercial-scale **DME (100 KTPA)** manufacturer
- The first and sole domestic manufacturer of **N-Methyl-2-Pyrrolidone (NMP)** in India
- Upcoming **HCN, Sodium Cyanide and EDTA** projects further strengthen import-replacement portfolio

Growth Without Leverage

- Standalone business remains **debt-free**
- Expansion funded largely through internal accruals
- Strong balance sheet with **₹2,152 Cr net worth** provides downside protection

Structural Margin Expansion

- Indigenous technology with **no royalty burden**
- Backward integration and methylamines scale-up driving cost leadership
- EBITDA margin targeted at **22-23% in FY27** vs ~20% in FY26

Balaji Amines is transitioning from an amines manufacturer to a speciality chemicals platform, driven by import substitution, EV-linked products, strong balance sheet strength and a large earnings-led capex payoff cycle.

Balaji Speciality Chemicals

Product	Existing Licensed Capacity (TPA)	Proposed Capacity (TPA)	Total Capacity after Expansions (TPA)	Application Areas
Ethylenediamine	37,350	-	37,350	Pharma, Fungicides, Pesticides, Polymers and Coatings
Piperazine	4,050	3,300	7,350	Pharma, Oilfield
Diethylenetriamine	3,150	8,900	12,050	Coatings, Polymers, Pharma
Mixture of Amines (AEP, AEEA, HEP)	780	1,000	1,780	Multiple Industries
Mixture of TEPA & PEHA	-	1,000	1,000	Epoxy curing agents, Polyamide resins, Corrosion inhibitors, Adhesives and Sealants
Hydrogen Cyanide	-	10,000	10,000	Pharmaceuticals and agrochemicals, Mining chemicals
Sodium Cyanide (100% Pellet)	-	12,000	12,000	Gold and silver mining, Electroplating, Chemical intermediates
Triethylenetetraamine (TETA)	-	3,000	3,000	Epoxy curing agents, Polyamide resins, Fuel additives, Corrosion inhibitors
Ammonium Sulphate	-	7,500	7,500	Fertilizers, Industrial applications, Chemical intermediates
Sodium Sulphate	-	5,300	5,300	Detergents and soaps, Glass manufacturing, Textile processing, Pulp and paper
Ethylene Diamine Tetra Acetic Acid (EDTA) & Ethylene Diamine Tetra Acetic Acid Disodium (EDTA-2Na)	-	5,000	5,000	Pharmaceuticals, Detergents and cleaning formulations
Total	45,330	57,000	1,02,330	

Manufacturing Capacity to Capture Future Demand


Balaji Amines

Product	Existing Licensed Capacity (TPA)	Proposed Capacity (TPA)	Total Capacity after Expansions (TPA)	Application Areas
Methyl Amine	88,000	-	88,000	Pharma, Agro, Dye & Rubber
Ethyl Amine	22,500	-	22,500	Pharma, Agro, Dye & Rubber
DMAHCL / DMAC	31,000	7,500	38,500	Pharma
Choline Chloride 60% (Corn Cob)	6,000	-	6,000	Animal Feed
Choline Chloride 75% & 98%	6,000	-	6,000	Animal Feed
2P / NEP	33,000	-	33,000	Pharma, Agro, Petro, Dyes, Paints
NMP		-		Pharma, Agro, Petro, Dyes, Paints
GBL		-		Pharma, Agro, Petro, Dyes, Paints
DMU	3600	-	3600	Pharma, Textile, Agro
DMAE / DEAE	2,000	-	2,000	Cosmetics
Morpholine	10,000	-	10,000	Pharma, Agro, Dyes, Paints, Textile, Rubber
Other HCL'S	750	-	750	Animal Feed
DMF	30,000	-	30,000	Pharma, Agro, Polymers, Petro, Dyes, Paints
Acetonitrile (ACN)	9,000	9,000	18,000	Pharma, Petro, Textile, Plastics
PVP K-30	750	-	750	Pharma, Agro, Cosmetics
Di-methyl Carbonate (DMC)	15,000	-	15,000	Pharma, Polycarbonate, Automobiles
Propylene Glycol (PG)	15,000	-	15,000	Food Grade
Dimethyl Ether (DME)	1,00,000	-	1,00,000	Replacement of LPG
n-Butylamine	15,000	-	15,000	Pharma, Agro
N-Methyl Morpholine (NMM)	-	5,000	5,000	Pharma , Oil & Gas
MIPA/DIPA	6,000	-	6,000	Pharma, Agro, Dyestuff
Total	3,93,600	21,500	4,15,100	

A Diversified Product Portfolio

	Amines	Amine Derivatives	Speciality & Other Chemicals
 Description	- The foundation of Balaji Amines' integrated value chain, supplying essential building blocks for a wide range of downstream chemicals. - The segment serves diverse industries through high-quality, vertically integrated manufacturing.	- Value-added products that expand the Company's presence across pharmaceutical, agrochemical and industrial applications. - This segment enhances product diversification while increasing value addition..	A high-value portfolio serving advanced applications across pharmaceuticals, EV batteries and speciality industries. Driven by indigenous technology and import substitution, the segment supports Balaji's future growth strategy.
 Products	- Mono Methyl Amine (MMA) - Di Methyl Amine (DMA) - Tri Methyl Amine (TMA) - Mono Ethyl Amine (MEA) - Di Ethyl Amine (DEA) - Tri Ethyl Amine (TEA) - N-Butylamine, Isopropylamine - Dimethyl Amino Ethanol - Diethyl Amino Ethanol	- DMAC - DMA HCL - DMU - Corn Cob - Aqueous Solution	- Morpholine - Acetonitrile (ACN) - DME - DMF - NMP - GBL - DMC, Gamma-butyrolactone - Propylene Carbonate (PC) - Propylene Glycol (PG) 2-Pyrrolidone, NEP, PVPK
 Application	- Pharma - Agro - EV Battery - Photographic chemicals - Rocket fuel - Dyestuff intermediates - Rubber chemicals, etc	- Pharma - Pesticides - Performance chemicals - Speciality chemicals - Animal/poultry feed additive etc.	- Production of Water Treatment chemicals and pesticide formulations - Fuel Additives and EV Battery Chemicals - Solvents across industries like pharmaceuticals, petrochemicals, dyes, Agro and paint industries - Formulations and Intermediates in pharmaceuticals - Lubricant Manufacturing

Integrated Across the Value Chain



Vertical Integration

Complete control from raw materials to speciality chemicals, enabling cost efficiency, quality consistency and supply reliability

90 - 95% of domestic demand met

For select key products, Balaji Amines' domestically developed processes. BAL demonstrating supply chain leadership at national scale, not just commercial scale

Diversified End Markets

Serving multiple high-growth industries including pharmaceuticals, agrochemicals, EV batteries, electronics and industrial chemicals

About Balaji Speciality Chemicals (BSCL)

Strategic Growth Platform

Balaji Speciality Chemicals Limited (BSCL), a 55% subsidiary of Balaji Amines Limited, is our strategic platform for high-value speciality chemicals. Located in Solapur, Maharashtra, BSCL commenced commercial operations in 2019 and is strengthening India's import substitution capabilities through speciality amines and derivatives. It obtained Mega project status by Government of Maharashtra.

Key Highlights



45,330 MTPA

Installed manufacturing capacity



Expanding Capacity – 57,000 MTPA

Addition of HCN, NACN and EDTA Plants



Import Substitution

Manufactures high-value speciality amines and derivatives



Global Presence

Exports to USA, Europe and other global markets



Why BSCL Matters



Sole Indian manufacturer of key speciality amines and derivatives – **EDA, DETA, PIP, AEEA and AEP**.



REACH registrations* for EDA, DETA and AEEA strengthen our access to regulated international markets.



A key growth engine supporting Balaji Amines' **long-term growth strategy** and value creation.

REACH is a European Regulation and is an acronym for the Registration, Evaluation, Authorisation and Restriction of Chemicals.

Trusted by Industry Leaders Across the Globe

Amines



Amine Derivatives




Speciality & Other Chemicals



Serving Diverse End Markets



Industry Wise – Revenue Breakup



Expanding Global Footprints

Country

- | | |
|--------------|--------------|
| UK | Finland |
| US | Indonesia |
| Argentina | Switzerland |
| Canada | Sri Lanka |
| Israel | Russia |
| India | Malaysia |
| Pakistan | Singapore |
| Bangladesh | Bahrain |
| Oman | Jordan |
| Germany | Guatemala |
| Italy | Colombia |
| Egypt | Costa Rica |
| South Africa | Thailand |
| Korea | Morocco |
| Taiwan | Peru |
| Spain | Venezuela |
| France | Philippines |
| Belgium | Saudi Arabia |
| Netherlands | Vietnam |
| Norway | Ireland |
| Poland | Qatar |
| Ukraine | Kuwait |
| Mexico | Denmark |
| Brazil | |
| Australia | |
| China | |
| Japan | |
| Turkey | |



OUR EXPORT PRESENCE

Delivering our products to
50+ countries across the world



Balaji AMINES LIMITED
...A Speciality Chemical Company

HOTEL BALAJI SAROVAR



About Balaji Sarovar Premiere Hotel

- Commenced Operations in October 2013 Hotel Balaji Sarovar Premier is the only 5 star hotel in Solapur
- Invested Rs. 110 crore in the Hotel Project via mix of Debt and Equity
- Tied up with Sarovar Group for the Management of the Hotel on Management Fee + Revenue Share model
- Solapur is an important Tourist hub owing to its close proximity to Pandharpur, Tuljapur, Siddeshwar Temple, Ganagapur, Bijapur and Akkalkot
- Solapur attracts millions of Tourists and pilgrims every year
- Presently average occupancy is around 80% and yielding good revenue.



Hotel project has resulted in substantial cash flow savings

Balaji Sarovar Premiere – Q1 FY27 Operating Matrix

Renowned Five Star Hotel In the City of Solapur



129 Rooms



Constitutes
1.73% of Total Revenue



Rs. 799 Lakhs
Revenue from Hotel Division



Rs. 5242 ARR



68%
Occupancy Rate



Rs. 3549
RevPAR











HISTORICAL PERFORMANCE



Consolidated Performance Highlights



Strong Core ROCE Profile

Particulars (Rs. Crs.)	FY26	FY25
Consolidated Debt	133	11
Consolidated Networkth	2152	2018
Total Capital Employed	2285	2029
Less: Investment in Hotel Balaji Sarovar & Others	95	117
Add: Loss in Hotel Balaji Sarovar & Others	35	43
Less: Investments in Capital Work in Progress in Greenfield project (Unit 4), Plant in Unit 3, Unit 1	187	173
Less: Investments by BSCL in Capital Work in Progress in Brownfield project (Unit 1) & Greenfield project (Unit 2)	343	116
Core Chemical Business Capital Employed (A)	1695	1666
EBIT on Consolidated Basis	238	217
Less: EBIT Loss Specific to Hotel Balaji Sarovar & Others	11	10
Core Chemical Business EBIT (B)	227	207
ROCE for Core Chemical Business (B/A)	13%	12%
ROCE at Consolidated Entity Level	14%	11%

Quarter ended June 2027:

The capital work-in-progress across various units, totalling to Rs. 165.60 crore, pertains to projects currently under development, which have yet to contribute to revenue. These include:


- 1) The Upgraded Acetonitrile (ACN) Plant
- 2) The N-Methyl Morpholine (NMM) plant

The capital work-in-progress at the subsidiary Balaji Speciality Chemicals Ltd (BSCL) amounts to Rs. 401.06 crore, and is allocated towards

- 1) A greenfield expansion to manufacture HCN, NaCN, EDTA, EDTA-Na, and other advanced chemical products
- 2) Brownfield expansions for EDA-based chemical production

Core chemical business continues to deliver a superior RoCE, reflecting the strong fundamentals and manufacturing capabilities that Balaji Amines has built over the years.

Consistent Dividend Payout



Particulars (Rs. per share)	FY21	FY22	FY23	FY24	FY25	FY26
Consolidated Book Value	281	406	524	584	623	664
Consolidated EPS	74	114	100	63	49	52
Dividend	4.00	6.00	10.00	11.00	11.00	11.00



LEADERSHIP & RESPONSIBILITY



Highly Experienced Management Team



MR. A. PRATHAP REDDY

Executive Chairman

- Civil Engineer by Education. Incorporated BAL in 1988
- BAL's continuing success is a testimony to his entrepreneurial skills.
- His vision has made BAL today as one of the leading players in chemical industry.



MR. N. RAJESHWAR REDDY

Whole Time Director

- Commerce Graduate having over 48 years of experience across industries
- Instrumental in project commissioning with indigenous approach to improve return profile
- Responsible for operations in Solapur



MR. D. RAM REDDY

Managing Director

- 45 years of experience across various businesses.
- Focused on establishing customer and supplier's relationship with leading buyers and suppliers
- Responsible for the supply chain, sales and marketing
- Has been awarded the Lifetime Achievement Award from Punyashlok Ahilyadevi Holkar Solapur University in July` 24



MR. A. SRINIVAS REDDY

Whole Time Director & CFO

- Post Graduate in Computer Science and completed Executive Management Programme at ISB Hyderabad.
- More than 28 years experience in multiple Project Management Roles
- He is presently responsible for projects

Awards & Certificates – A Testimony of our capabilities



ISO Certificate



Three Star Export House



ISO Certificate



BEST CEO (CHEMICAL INDUSTRY) AWARD TO SHRI ANDE PRATHAP REDDY BY BUSINESS TODAY GROUP



ISO 9001 : 2015 Certificate



Certificate of Merit - CHEMEXCIL



First Award - CHEMEXCIL



WHO GMP Certificate

Awards & Recognition - A Testimony of our capabilities



Balaji Amines Limited has received the Best Project Award in the area of Healthcare, under the Large Enterprise category by Rotary India, National CSR Awards 2025



Balaji Amines Limited has been awarded as Sustainability Leader of the Year in Chemicals at FICCI Chemicals and Petrochemicals Awards 2025 by FICCI (Federation of Indian Chambers of Commerce and Industry)



Balaji Sarovar Premiere, has been honoured with the Food Connoisseurs India Award for Restaurant Serving the best Chinese cuisine- 2026



Balaji Amines Limited has been conferred with the Narayan Meghaji Lokhande Occupational Safety & Health Award 2026 by the Directorate of Industrial Safety and Health (DISH), Government of Maharashtra.



On October 8, 2025, Balaji Amines Limited bagged the Western Zone Award in the Large-Scale Enterprise category for its outstanding work in the Healthcare Sector

ESG & CSR Initiatives



Constructed Classroom at ZPHS Chengal School, Mandal Bhimgal, Nizamabad, dt. 04.01.2025



Construction of Toilet Block at Indira Kale Prashala, Jalkotwadi, dt. 25.03.2025



Distributed Sanitary Napkin Incinerator and Vending Machine at Vishwabhusan Vidyalay, Solapur dt.30.09.2024



Distribution of Helmets for Highway Safety Squad Sambhaji Nagar dt. 17.02.2025



Distribution of SSC Board Exam Books in Solapur and Dharashiv dt. 15.01.2025



MPSC & UPSC competitive Examination Books and 1 Public System to Telugu Bhasha Abhivrudhhi Sarvajanik Granthalayam, Solapur dt. 20.08.2024



Sponsorship to Sandhyarani Bandgar Tennis Player ITF Team Championship Turkey 09-03-2025

COMPANY :



Balaji Amines Limited

CIN-L24132MH1988PLC049387

Investor Relations Team

Email- cs@balajiamines.com

www.balajiamines.com

INVESTOR RELATIONS ADVISORS :



MUFG Intime India Private Limited

A part of MUFG Corporate Markets, a division of
MUFG Pension & Market Services

Mr. Nikunj Seth

nikunj.seth@in.mpms.mufg.com

Ms. Sakshi Mehta

sakshi.mehta@in.mpms.mufg.com

Meeting Request

[Link](#)

THANK YOU

